keyword
MENU ▼
Read by QxMD icon Read
search

Telbivudine

keyword
https://www.readbyqxmd.com/read/29344772/safety-and-efficacy-of-lamivudine-or-telbivudine-started-in-early-pregnancy-for-mothers-with-active-chronic-hepatitis-b
#1
Tianyu He, Yuqing Bai, Haodong Cai, Xiaojuan Ou, Min Liu, Wei Yi, Jidong Jia
BACKGROUND: Few data exist regarding use of nucleos(t)ide analogs started in early pregnancy for mothers with active chronic hepatitis B (CHB). We assessed the safety and efficacy of lamivudine/telbivudine initiated in the first trimester versus no treatment in mothers with active CHB. METHODS: We retrospectively enrolled 94 mothers newly diagnosed with active CHB in the first trimester of pregnancy. Patients with or without antiviral therapy were followed until postpartum week 28...
January 17, 2018: Hepatology International
https://www.readbyqxmd.com/read/29325289/-optimal-treatment-regimen-for-patients-with-hbeag-positive-chronic-hepatitis-b-after-suboptimal-response-to-24-weeks-of-peg-ifn-%C3%AE-2a
#2
X D Luo, X P Chen, X F Chen
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group (n = 93) and telbivudine group (n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA < 500 IU/ml), safety, and drug resistance rate...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29274174/prophylactic-antiviral-therapy-for-the-prevention-of-mother-to-child-transmission-of-hepatitis-b-virus-can-be-stopped-at-delivery
#3
Qing-Lei Zeng, Guang-Hua Xu, Ben Wang, Zhi-Qin Li, Zu-Jiang Yu
Many studies have demonstrated that antiviral therapy has an important role in the prevention of mother-to-child transmission of hepatitis B virus (HBV)1-3 , including a recent article by Han et al. who reported that the majority of mothers stopped prophylactic telbivudine at 1 month postpartum.4 However, the HBV Guidelines of the AASLD (at delivery to 3 months postpartum),1 EASL (within and at 12 weeks postpartum in 2012 and 2017, respectively),2 and APASL (at delivery)3 had different recommendations regarding stopping time of antivirals given as prophylaxis, which result in differing durations worldwide...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29207359/telbivudine-attenuates-uuo-induced-renal-fibrosis-via-tgf-%C3%AE-smad-and-nf-%C3%AE%C2%BAb-signaling
#4
Jie Chen, Detian Li
Renal fibrosis yields decreased renal function and is a potent contributor to chronic kidney disease (CKD). Telbivudine (LdT) is an anti-hepatitis B virus (HBV) drug that has been found to steadily improve renal function, but the mechanism of drug action is unclear. One explanation is that LdT impacts inflammatory or fibrotic pathways. In this study, we investigated renal protection by LdT in a rat model of unilateral ureteral obstruction (UUO). UUO rats received oral gavage of LdT (1, 1.5, or 2g/kg/day) for 5weeks...
December 2, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29193547/safety-and-efficacy-of-telbivudine-in-late-pregnancy-to-prevent-mother-to-child-transmission-of-hepatitis-b-virus-a-multicenter-prospective-cohort-study
#5
Yali Hu, Chenyu Xu, Biao Xu, Lingqing Hu, Qin Liu, Jie Chen, Jingli Liu, Lanhua Liu, Jishi Yang, Tingmei Chen, Jian Wen, Na Jiang, Yaguang Zhang, Minkai Cao, Jing Feng, Xiaoqian Lin, Zhiqun Wang, Biyun Xu, Yi-Hua Zhou
Infection of hepatitis B virus (HBV) occurs in ~10% of infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg) after immunoprophylaxis. We aimed to evaluate the safety and efficacy of telbivudine used during late pregnancy for preventing mother-to-child transmission of HBV. We conducted a multicenter prospective cohort study in five hospitals from 2012-2014, which enrolled HBV-infected singleton pregnant women with positive HBeAg. By their choice, women were divided into therapy (telbivudine 600 mg/day, from gestation 28-32 weeks to 3-4 weeks postpartum) and control (no antiviral agent) groups...
November 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29193536/temporal-trend-and-risk-determinants-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients-on-entecavir-or-tenofovir
#6
Yao-Chun Hsu, Hsiu-J Ho, Teng-Yu Lee, Yen-Tsung Huang, Ming-Shiang Wu, Jaw-Town Lin, Chun-Ying Wu, Hashem B El-Serag
This study aimed to elucidate the temporal change and determinants for the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B continuously receiving nucleos(t)ide analogues. Through analysis of the national healthcare database in Taiwan, we screened a total of 65,426 infected patients receiving entecavir or tenofovir for at least 3 months and excluded those with lamivudine, adefovir or telbivudine exposure, malignancy, end-stage renal failure, or a diagnosis of HCC within 3 months of starting treatment...
November 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29179767/rhabdomyolysis-lactic-acidosis-and-multiple-organ-failure-during-telbivudine-treatment-for-hepatitis-b-a-case-report-and-review-of-the-literature
#7
Jinxin Zheng, Minggui Deng, Xiaoliang Qiu, Zhong Chen, Duoyun Li, Xiangbin Deng, Qiwen Deng, Zhijian Yu
BACKGROUND: Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. However, reported cases of telbivudine leading to multiple organ failure are rare. Here, we report a case of telbivudine-induced severe polymyositis, lactic acidosis, and multiple organ failure. CASE PRESENTATION: A 30-year-old Chinese man with hepatitis B virus infection received antiviral treatment with 600 mg of telbivudine daily for more than 11 months...
November 27, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29148589/determination-of-telbivudine-in-the-plasma-of-chronic-hepatitis-b-patients-in-long-term-treatment-by-high-performance-liquid-chromatographic-tandem-mass-spectrometry
#8
Bicui Chen, Li Chen, Cai Cheng, Mingkang Zhong, Xiaojin Shi, Jiming Zhang, Bin Wang
Usually, creatine kinase elevation is commonly reported in telbivudine-treated patients. However, little is known abosut the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC-MS/MS for the determination of telbivudine in a clinical study of chronic hepatitis B (CHB) patients. The assay was linear in a dynamic 10-10,000 ng/mL range (r(2) > 0.999) and total analysis time was 6 min in this method...
November 17, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29095799/comparing-efficacy-of-lamivudine-adefovir-dipivoxil-telbivudine-and-entecavir-in-treating-nucleoside-analogues-na%C3%A3-ve-for-hbeag-negative-hepatitis-b-with-medium-hepatitis-b-virus-hbv-dna-levels
#9
Hong Shi, Zongping Han, Jian Liu, Jinfang Xue, Shuya Zhang, Zhe Zhu, Jinyu Xia, Mingxing Huang
BACKGROUND The antiviral effect of HBV in different nucleos (t) ide analogues is still not well known. This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA. MATERIAL AND METHODS The effective data of 207 patients treated by LMV (n=43), ADV (n=57), LdT (n=54) or ETV (n=53) were collected and analyzed during 144-week follow-up by retrospective analysis...
November 2, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29093232/treatment-response-monitoring-of-chronic-hepatitis-b-patients-using-transient-elastography-and-aspartate-aminotransferase-to-platelet-ratio-index-apri
#10
Ignatius R Tenggara, C Rinaldi Lesmana, Rino A Gani
BACKGROUND: Hepatitis B is endemic in Indonesia and treatment response need to be monitored during and after antiviral therapy. Liver stiffness measurement and alanine aminotransferase-to-platelet ratio index (APRI) are noninvasive method to detect liver fibrosis available in Indonesia. However, little is known about their ability to evaluate treatment response in chronic hepatitis B (CHB) patients in Indonesia. This study aimed to investigate liver stiffness changes by transient elastography (TE) and APRI before and after one-year oral antiviral treatment in CHB patients and the correlation between TE and APRI...
July 2017: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/29082653/telbivudine-therapy-for-gravidas-with-chronic-hepatitis-b-infection-and-patients-at-risk-of-renal-impairment
#11
REVIEW
J Liu, T Chen, Y Zhao
Hepatitis B virus infection is currently the most important cause of chronic viral hepatitis worldwide and is one of the most frequent causes of end-stage liver disease. With the international implementation of the hepatitis B vaccine and combined prophylaxis for infants born to HBsAg(+) mothers, the prevalence of hepatitis B has decreased remarkably. However, intra-uterine transmission has become a critical bottleneck for eliminating hepatitis B infection. The efficacy of nucleos(t)ide analogs on inhibiting hepatitis B replication has been widely confirmed, and the quality of life and the survival of individuals with chronic hepatitis B (CHB) have improved to a great degree...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082652/long-term-outcome-of-telbivudine-versus-entecavir-in-treating-higher-viral-load-chronic-hepatitis-b-patients-without-cirrhosis
#12
H-Y Pan, H-Y Pan, W-Y Song, W Zheng, Y-X Tong, D-H Yang, Y-N Dai, M-J Chen, M-S Wang, Y-C Huang, J-J Zhang, H-J Huang
Chronic hepatitis B (CHB) patients with higher hepatitis B virus (HBV) load (higher viral load [HVL], HBV DNA ≥1 × 107 copies/mL) require antiviral therapy, but data for evaluating the long-term outcome of this therapy with antiviral agents remain limited. We comparatively evaluated the efficacy and the safety of nucleoside analogues in 179 noncirrhotic CHB patients with HVL over 5 years. The HBeAg-positive (n = 104) or HBeAg-negative (n = 75) patients were treated consecutively with telbivudine (LdT, n = 88) or entecavir (ETV, n = 91) and evaluated for viral response, drug resistance and safety...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082651/comparison-of-208-week-sequential-therapy-with-telbivudine-and-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24%C3%A2-weeks-of-peg-ifn%C3%AE-2a-therapy-an-open-labelled-randomized-controlled-real-life-trial
#13
X D Luo, X F Chen, Y Zhou, X P Chen
The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082650/prospective-cohort-study-on-the-efficacy-and-safety-of-telbivudine-used-throughout-pregnancy-in-blocking-mother-to-child-transmission-of-hepatitis-b-virus
#14
W Yi, M-H Li, Y Xie, J Wu, Y-H Hu, D Zhang, Y Zhang, W-H Cao
Women with chronic hepatitis B should maintain nucleotide analogue treatment to prevent disease progression during pregnancy. The aim of this study was to prospectively evaluate the efficacy and safety of telbivudine used throughout pregnancy for preventing hepatitis B virus (HBV) mother-to-child transmission (MTCT). From January 2012 to June 2014, women who were receiving telbivudine therapy and became pregnant were enrolled in group A at 28 weeks of gestation. Pregnant women with an HBV DNA level >106  IU/mL were enrolled in either group B (telbivudine started at 28 weeks of gestation) or group C (control group without treatment)...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082647/improvement-of-telbivudine-on-renal-function-and-massive-proteinuria-a-case-report
#15
J Liu, N Yao, Y Zhao
The quality of life and extended survival of patients with chronic hepatitis B (CHB), especially those with decompensated liver cirrhosis, has been improved markedly with nucleos(t)ide analogs treatment. In such conditions, the influence of hepatitis B virus (HBV) infection and antiviral agents on renal function becomes a consideration with long-term use and ageing. Membranous glomerulonephritis has been confirmed as the most common histological renal lesion. In this study, we reported a CHB patient with decompensated cirrhosis showing a significant improvement in massive proteinuria along with elevation of estimated glomerular filtration rate (eGFR) after 1 year treatment with telbivudine...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082646/safety-and-efficacy-of-telbivudine-for-chronic-hepatitis-b-during-the-entire-pregnancy-long-term-follow-up
#16
J Shang, Q Wen, C C Wang, K Liu, L Bai, H Tang
The management of hepatitis B virus (HBV) infection in pregnancy is a unique issue. Telbivudine (LdT) is recommended to block HBV mother-to-child transmission (MTCT) in the third trimester. However, the safety of LdT treatment during the entire pregnancy for the long-term growth of infants is unclear. The aim of this study was to evaluate the efficacy and long-term safety of LdT for the entire pregnancy period. This retrospective cohort study included 40 pregnant women and 43 children from 2011 to 2017. The antiviral effects and maternal abnormalities were evaluated...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082645/efficacy-and-safety-of-three-adefovir-based-combination-therapies-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-response-to-adefovir-monotherapy
#17
M-L Wang, E-Q Chen, D-M Zhang, L-Y Du, L-B Yan, T-Y Zhou, X-Z Lei, B-J Lei, J-J Lu, J Liao, H Tang
Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost. Therefore, the management of patients who have failed ADV therapy or who sustained renal damage during ADV therapy remains an important clinical problem in China. This retrospective study aimed to compare the efficacy and safety of lamivudine (LAM), telbivudine (LdT) or entecavir (ETV) add-on strategies to optimize the treatment of patients with prior suboptimal response to ADV monotherapy...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29080299/interpretation-of-liver-stiffness-measurement-based-approach-for-the-monitoring-of-hepatitis-b-patients-with-antiviral-therapy-a-2-year-prospective-study
#18
X Liang, Q Xie, D Tan, Q Ning, J Niu, X Bai, S Chen, J Cheng, Y Yu, H Wang, M Xu, G Shi, M Wan, X Chen, H Tang, J Sheng, X Dou, J Shi, H Ren, M Wang, H Zhang, Z Gao, C Chen, H Ma, Y Chen, R Fan, J Sun, J Jia, J Hou
Liver biopsy is not routinely performed in treated chronic hepatitis B. Liver stiffness measurement has been validated for noninvasive liver fibrosis assessment in pretreatment chronic hepatitis B but has not been assessed for fibrosis monitoring during antiviral therapy. Liver stiffness was systemically monitored by Fibroscan® every 6 months in a cohort of patients with hepatitis B receiving antiviral therapy and compared with liver biopsies at baseline and week 104. A total of 534 hepatitis B e antigen-positive treatment-naive patients receiving telbivudine-based therapy with qualified liver stiffness measurement at baseline and week 104 were analyzed, 164 of which had adequate paired liver biopsies...
October 27, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29077211/switching-from-tenofovir-and-nucleoside-analogue-therapy-to-tenofovir-monotherapy-in-virologically-suppressed-chronic-hepatitis-b-patients-with-antiviral-resistance
#19
Dong Yun Kim, Hye Won Lee, Jeong Eun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
It is unclear whether chronic hepatitis B (CHB) patients with antiviral resistance, who achieve a complete virologic response (CVR) with tenofovir disoproxil fumarate (TDF) and nucleoside analogue (NUC) combination therapy, maintain CVR if switched to TDF monotherapy. We investigated the persistence of CVR after cessation of NUC in virologically suppressed antiviral resistant CHB patients using TDF+NUC combination therapy. This study recruited 76 antiviral-resistant CHB patients showing CVR on TDF+entecavir (ETV) (n = 52), TDF+lamivudine (LAM; n = 14), and TDF+telbivudine (LdT; n = 10) combination therapy, who were switched to TDF monotherapy as step-down therapy...
October 27, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/29056010/-predictive-value-of-single-nucleotide-polymorphisms-of-hla-c-and-ube2l3-in-evaluating-the-effect-of-telbivudine-antiviral-therapy-during-pregnancy
#20
J F Liu, J Wang, D D Guo, C J Qi, F R Cao, Z Tian, N J Yao, Y C Wu, Y Yang, Y L He, Y R Zhao, T Y Chen
Objective: To investigate the association between single nucleotide polymorphisms (SNPs) of rs3130542 and rs4821116 in the HLA-C and UBE2L3 genes and the effect of telbivudine antiviral therapy during pregnancy in HBeAg-positive mothers through a large-sample control study, and to provide a basis for the development of individualized blocking strategies for pregnant women with a high viral load. Methods: The genotypes of rs3130542 and rs4821116 were determined for 312 pregnant women with a high viral load who received telbivudine antiviral therapy during the second or third trimester of pregnancy, and the dominant model, recessive model, and additive model were used to analyze the association between the genotypes of these two loci and the reduction in HBV DNA load...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
2108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"